SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.7444
-0.0264 (-3.43%)
At close: May 15, 2026, 4:00 PM EDT
0.7400
-0.0044 (-0.59%)
After-hours: May 15, 2026, 4:10 PM EDT
SCYNEXIS Revenue
SCYNEXIS had revenue of $18.90M in the twelve months ending March 31, 2026, up 618.63% year-over-year. In the year 2025, SCYNEXIS had annual revenue of $20.60M with 449.95% growth.
Revenue (ttm)
$18.90M
Revenue Growth
+618.63%
P/S Ratio
2.89
Revenue / Employee
$1,130,222
Employees
18
Market Cap
58.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.60M | 16.86M | 449.95% |
| Dec 31, 2024 | 3.75M | -136.40M | -97.33% |
| Dec 31, 2023 | 140.14M | 135.05M | 2,652.72% |
| Dec 31, 2022 | 5.09M | -8.07M | -61.32% |
| Dec 31, 2021 | 13.16M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 121.00K | -136.00K | -52.92% |
| Dec 31, 2018 | 257.00K | - | - |
| Dec 31, 2017 | 257.00K | - | - |
| Dec 31, 2016 | 257.00K | - | - |
| Dec 31, 2015 | 257.00K | -999.00K | -79.54% |
| Dec 31, 2014 | 1.26M | -8.31M | -86.87% |
| Dec 31, 2013 | 9.57M | 156.00K | 1.66% |
| Dec 31, 2012 | 9.41M | -3.42M | -26.67% |
| Dec 31, 2011 | 12.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Assertio Holdings | 102.16M |
| InterCure | 84.76M |
| Rockwell Medical | 67.68M |
| Cumberland Pharmaceuticals | 41.94M |
| BGM Group | 25.10M |
| Zhengye Biotechnology Holding | 16.64M |
| China Pharma Holdings | 4.14M |
| BioXcel Therapeutics | 642.00K |
SCYX News
- 5 days ago - Scynexis reports Q1 EPS (42c), consensus (12c) - TheFly
- 5 days ago - SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 days ago - SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Scynexis files to sell 87M shares of common stock for holders - TheFly
- 6 weeks ago - SCYNEXIS Transcript: M&A announcement - Transcripts
- 6 weeks ago - Poxel announces sale of PXL770 to Scynexis for up to $196M - TheFly
- 6 weeks ago - Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Business Wire
- 6 weeks ago - Scynexis completes acquisition of PXL-770 for treatment of kidney disease - TheFly